AES 2022 | Using cenobamate earlier in the epilepsy treatment paradigm

Sean Stern, MS, SK Life Science, Inc., gives his thoughts on how the role of cenobamate in the epilepsy treatment paradigm will change over time. Cenobamate is typically employed in a more refractory population, as an adjunctive treatment after several other agents have failed to give seizure control. However, studies have shown that shorter duration of epilepsy and lower concomitant drug load are predictors of achieving and maintaining a response with cenobamate. As more evidence is gathered in a less refractory population, cenobamate may move to an earlier line of therapy where it is even more effective. This interview took place at the American Epilepsy Society (AES) Annual Meeting 2022 in Nashville, TN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.